February 11, 2021 09:00 AM ESTUpdated February 12, 11:57 PM

All in on ide-cel, Bristol Myers Squibb writes off $470M as second BCMA CAR-T is ejected from the pipeline

Amber Tong

With just a little over a month to go before the FDA is slated to decide on ide-cel, Bristol Myers Squibb is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Is there still hope for Summit's cancer drug buried in the data?

MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D

EMA considers serious eye condition a ‘very rare’ side effect of semaglutide

At a crossroads, biotechs are passing on reverse mergers in 2025

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...